Based on the Tarsus Pharmaceuticals Inc stock forecast from 4 analysts, the average analyst target price for Tarsus Pharmaceuticals Inc is USD 62.14 over the next 12 months. Tarsus Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Tarsus Pharmaceuticals Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Tarsus Pharmaceuticals Inc’s stock price was USD 44.83. Tarsus Pharmaceuticals Inc’s stock price has changed by -9.29% over the past week, +20.25% over the past month and +150.03% over the last year.
No recent analyst target price found for Tarsus Pharmaceuticals Inc
No recent average analyst rating found for Tarsus Pharmaceuticals Inc
Company Overview Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Read Less
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of...Read More
Frequently Asked Questions About Tarsus Pharmaceuticals Inc (TARS) Stock
Based on ratings from 4 analysts Tarsus Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 6 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on TARS's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for TARS is USD 62.14 over the next 12 months. The maximum analyst target price is USD 73 while the minimum anlayst target price is USD 41.
Unfortunately we do not have enough data on TARS's stock to indicate if its overvalued.
The last closing price of TARS's stock was USD 44.83.
The most recent market capitalization for TARS is USD 1.80B.
Based on targets from 4 analysts, the average taret price for TARS is projected at USD 62.14 over the next 12 months.
This means that TARS's stock price may go up by +38.62% over the next 12 months.
We can't find any ETFs which contains Tarsus Pharmaceuticals Inc's stock.
As per our most recent records Tarsus Pharmaceuticals Inc has 244 Employees.
Tarsus Pharmaceuticals Inc's registered address is 15440 Laguna Canyon Road, Irvine, CA, United States, 92618.
You can get more information about it from Tarsus Pharmaceuticals Inc's website at https://www.tarsusrx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Tarsus Pharmaceuticals Inc (TARS) Stock
Based on ratings from 4 analysts Tarsus Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 6 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on TARS's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for TARS is USD 62.14 over the next 12 months. The maximum analyst target price is USD 73 while the minimum anlayst target price is USD 41.
Unfortunately we do not have enough data on TARS's stock to indicate if its overvalued.
The last closing price of TARS's stock was USD 44.83.
The most recent market capitalization for TARS is USD 1.80B.
Based on targets from 4 analysts, the average taret price for TARS is projected at USD 62.14 over the next 12 months.
This means that TARS's stock price may go up by +38.62% over the next 12 months.
We can't find any ETFs which contains Tarsus Pharmaceuticals Inc's stock.
As per our most recent records Tarsus Pharmaceuticals Inc has 244 Employees.
Tarsus Pharmaceuticals Inc's registered address is 15440 Laguna Canyon Road, Irvine, CA, United States, 92618.
You can get more information about it from Tarsus Pharmaceuticals Inc's website at https://www.tarsusrx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TARS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
